acamprosate calcium enteric-coated

FDA Drug Profile — Acamprosate Calcium

Drug Details

Generic Name
acamprosate calcium enteric-coated
Brand Names
Acamprosate Calcium
Application Number
ANDA200142
Sponsor
Mylan Pharmaceuticals Inc.
NDC Codes
2
Dosage Forms
TABLET, DELAYED RELEASE
Routes
ORAL
Active Ingredients
ACAMPROSATE CALCIUM

Indications and Usage

1 INDICATIONS AND USAGE Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. • Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation ( 1 , 14 ). • Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support ( 1 ).